Pharmacy Benefit Managers in the Eye of the Storm: Growing Multipartite Scrutiny.

J Am Board Fam Med

From the Professor of Medical Science, Brown University, Providence, RI (EYA); Brown University Library, Providence, RI (DPO); University of Rochester School of Medicine and Dentistry, Rochester, NY (DSG); UF Health, University of Florida, Gainesville FL (DSG).

Published: January 2024

The high cost of prescription drugs in the U.S. remains an ongoing national challenge. A recurring focal point in discussions over this distressing steady state is the role(s) played by Pharmacy Benefit Managers (PBMs) who negotiate drug prices with pharmaceutical manufacturers, conduct drug utilization reviews, engage in disease management, and see to formulary creation. At their inception, the multiple newly established PBMs were arguably intent on constraining the rise of prescription drug prices. At the time of this writing, however, the lion share of a far less competitive PBM market is controlled by CVS Caremark, Express Scripts, and OptumRx. It is this evolving reality which could be interpreted to mean that the PBMs may have become part of the problem, rather than part of the solution. Expanded scrutiny of the PBMs by Federal and State authorities as well as by Professional Medical Associations must not be delayed with an eye toward affording the public with relief from the high cost of prescription drugs.

Download full-text PDF

Source
http://dx.doi.org/10.3122/jabfm.2023.230102R1DOI Listing

Publication Analysis

Top Keywords

pharmacy benefit
8
benefit managers
8
high cost
8
cost prescription
8
prescription drugs
8
drug prices
8
managers eye
4
eye storm
4
storm growing
4
growing multipartite
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!